Shots:
- Hansoh has reported the P-III (ARTEMIS-008) trial results assessing risvutatug rezetecan (Ris-Rez/HS-20093) vs topotecan in pts with advanced or relapsed SCLC after prior Pt-based therapy
- Trial met its 1EP of improved OS in the interim analysis, with consistent benefit also observed across 2EPs, incl. PFS; data will be presented at an upcoming conference
- Based on these findings, Hansoh Pharma plans to initiate communications with China’s NMPA CDE to advance preparations for a BLA
Ref: Hansoh | Image: Hansoh | Press Release
Related News: Hansoh Pharmaceutical Reports the EC Approval of Aumseqa for Non-small Cell Lung Cancer (NSCLC)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
